Xilio Therapeutics, Inc.
XLO
$0.71
-$0.03-4.44%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 588.40% | 536.44% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 588.40% | 536.44% | -- | -- | -- |
| Cost of Revenue | 34.93% | 132.61% | -- | -- | -- |
| Gross Profit | 112.41% | -25.16% | -- | -- | -- |
| SG&A Expenses | 16.92% | 15.41% | 5.49% | -8.22% | -14.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.91% | 3.75% | -8.20% | -16.61% | -18.30% |
| Operating Income | 31.76% | 15.07% | 21.05% | 24.63% | 23.79% |
| Income Before Tax | 6.87% | 14.21% | 23.47% | 23.77% | 22.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.87% | 14.21% | 23.47% | 23.77% | 22.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.87% | 14.21% | 23.47% | 23.77% | 22.67% |
| EBIT | 31.76% | 15.07% | 21.05% | 24.63% | 23.79% |
| EBITDA | 32.43% | 15.24% | 21.40% | 24.90% | 24.08% |
| EPS Basic | 55.50% | 58.46% | 64.29% | 51.20% | 39.33% |
| Normalized Basic EPS | 54.64% | 57.75% | 63.81% | 52.41% | 40.47% |
| EPS Diluted | 55.50% | 58.46% | 64.29% | 51.28% | 39.42% |
| Normalized Diluted EPS | 54.64% | 57.75% | 63.81% | 52.41% | 40.47% |
| Average Basic Shares Outstanding | 105.86% | 100.61% | 123.42% | 81.85% | 48.29% |
| Average Diluted Shares Outstanding | 105.86% | 100.61% | 123.42% | 81.85% | 48.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |